Palvella Therapeutics, Inc. (PVLA)
NASDAQ: PVLA · Real-Time Price · USD
131.69
+8.52 (6.92%)
Apr 9, 2026, 12:35 PM EDT - Market open
Palvella Therapeutics Stock Forecast
Stock Price Forecast
The 15 analysts that cover Palvella Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $171.87, which forecasts a 30.51% increase in the stock price over the next year. The lowest target is $38 and the highest is $270.
Price Target: $171.87 (+30.51%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Palvella Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 9 | 12 | 12 | 12 | 11 |
| Buy | 4 | 4 | 4 | 5 | 5 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 13 | 16 | 17 | 17 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $210 → $240 | Strong Buy | Maintains | $210 → $240 | +82.25% | Mar 31, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $255 → $270 | Strong Buy | Maintains | $255 → $270 | +105.03% | Mar 24, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $210 | Strong Buy | Maintains | $210 | +59.47% | Mar 16, 2026 |
| Mizuho | Mizuho | Buy Maintains $205 → $250 | Buy | Maintains | $205 → $250 | +89.84% | Feb 25, 2026 |
| BTIG | BTIG | Strong Buy Maintains $192 → $215 | Strong Buy | Maintains | $192 → $215 | +63.26% | Feb 25, 2026 |
Financial Forecast
Revenue This Year
27.20K
Revenue Next Year
27.88M
from 27.20K
Increased by 102,383.51%
EPS This Year
-5.11
from -3.71
EPS Next Year
-6.47
from -5.11
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 420,000 | 77.4M | |||
| Avg | 27,203 | 27.9M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 284,368.1% | |||
| Avg | - | 102,383.5% | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -3.32 | -2.87 | |||
| Avg | -5.11 | -6.47 | |||
| Low | -6.37 | -12.32 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.